William J. Lane

William J. Lane

Auto-generated profile, based on publicly available information

William J. Lane

Department of Pathology Brigham and Women's Hospital Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
SSSiranush Sarkizova
Siranush Sarkizova
SKSusan Klaeger
Susan Klaeger
PLPhuong M. Le
Phuong M. Le
LLLetitia W. Li
Letitia W. Li
GOGiacomo Oliveira
Giacomo Oliveira
DKDerin B. Keskin
Derin B. Keskin

1 June 2018 in The Lancet Haematology
Verified
Journal Article
Closed access
WLWilliam J Lane
William J Lane
CWConnie M Westhoff
Connie M Westhoff
NGNicholas S Gleadall
Nicholas S Gleadall
MAMaria Aguad
Maria Aguad
RSRobin Smeland-Wagman
Robin Smeland-Wagman
SKSek Won Kong
Sek Won Kong

19 July 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
MJMax Jan
Max Jan
MLMatthew J. Leventhal
Matthew J. Leventhal
EMElizabeth A. Morgan
Elizabeth A. Morgan
JWJordan C. Wengrod
Jordan C. Wengrod
ANAnwesha Nag
Anwesha Nag
BEBenjamin L. Ebert
Benjamin L. Ebert
Immune evasion is a hallmark of cancer and a central mechanism underlying acquired resistance to immune therapy. In allogeneic hematopoietic cell transplantation (alloHCT), late relapses can arise after prolonged alloreactive T-cell control, but the molecular mechanisms of immune escape remain unclear. To identify mechanisms of immune evasion, we performed a genetic analysis of serial samples from 25 patients with myeloid malignancies who relapsed ≥1 year after alloHCT. Using targeted sequencing and microarray analysis to determine HLA allele-specific copy number, we identified copy-neutral loss of heterozygosity events and focal deletions spanning class 1 HLA genes in 2 of 12 recipients of matched unrelated-donor HCT and in 1 of 4 recipients of mismatched unrelated-donor HCT. Relapsed clones, although highly related to their antecedent pretransplantation malignancies, frequently acquired additional mutations in transcription factors and mitogenic signaling genes. Previously, the study of relapse after haploidentical HCT established the paradigm of immune evasion via loss of mismatched HLA. Here, in the context of matched unrelated-donor HCT, HLA loss provides genetic evidence that allogeneic immune recognition may be mediated by minor histocompatibility antigens and suggests opportunities for novel immunologic approaches for relapse prevention.

4 August 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
NGNicholas S. Gleadall
Nicholas S. Gleadall
BVBarbera Veldhuisen
Barbera Veldhuisen
JGJeremy Gollub
Jeremy Gollub
ABAdam S. Butterworth
Adam S. Butterworth
JOJohn Ord
John Ord
WLWilliam J. Lane
William J. Lane
Each year, blood transfusions save millions of lives. However, under current blood-matching practices, sensitization to non–self-antigens is an unavoidable adverse side effect of transfusion. We describe a universal donor typing platform that could be adopted by blood services worldwide to facilitate a universal extended blood-matching policy and reduce sensitization rates. This DNA-based test is capable of simultaneously typing most clinically relevant red blood cell (RBC), human platelet (HPA), and human leukocyte (HLA) antigens. Validation was performed, using samples from 7927 European, 27 South Asian, 21 East Asian, and 9 African blood donors enrolled in 2 national biobanks. We illustrated the usefulness of the platform by analyzing antibody data from patients sensitized with multiple RBC alloantibodies. Genotyping results demonstrated concordance of 99.91%, 99.97%, and 99.03% with RBC, HPA, and HLA clinically validated typing results in 89 371, 3016, and 9289 comparisons, respectively. Genotyping increased the total number of antigen typing results available from 110 980 to >1 200 000. Dense donor typing allowed identification of 2 to 6 times more compatible donors to serve 3146 patients with multiple RBC alloantibodies, providing at least 1 match for 176 individuals for whom previously no blood could be found among the same donors. This genotyping technology is already being used to type thousands of donors taking part in national genotyping studies. Extraction of dense antigen-typing data from these cohorts provides blood supply organizations with the opportunity to implement a policy of genomics-based precision matching of blood.

8 August 2019 in Transfusion
Verified
Journal Article
Open access
PDF file
WLWilliam J. Lane
William J. Lane
SVSunitha Vege
Sunitha Vege
HMHelen H. Mah
Helen H. Mah
CLChristine Lomas‐Francis
Christine Lomas‐Francis
MAMaria Aguad
Maria Aguad
FPfor the MilSeq Project
for the MilSeq Project
BACKGROUND: Genotyping has expanded the number red blood cell (RBC) and platelet (PLT) antigens that can readily be typed, but often represents an additional testing cost. The analysis of existing genomic data offers a cost‐effective approach. We recently developed automated software (bloodTyper) for determination of RBC and PLT antigens from whole genome sequencing. Here we extend the algorithm to whole exome sequencing (WES).STUDY DESIGN AND METHODS: Whole exome sequencing was performed on samples from 75 individuals. WES‐based bloodTyper RBC and PLT typing was compared to conventional polymerase chain reaction (PCR)RHDzygosity testing and serologic and single‐nucleotide polymorphism (SNP) typing for 38 RBC antigens in 12 systems (17 serologic and 35 SNPs) and 22 PLT antigens (22 SNPs). Samples from the first 20 individuals were used to modify bloodTyper to interpret WES followed by blinded typing of 55 samples.RESULTS: Over the first 20 samples, discordances were noted for C, M, and N antigens, which were due to WES‐specific biases. After modification, bloodTyper was 100% accurate on blinded evaluation of the last 55 samples and outperformed both serologic (99.67% accurate) and SNP typing (99.97% accurate) reflected by two Fyband one N serologic typing errors and one undetected SNP encoding a Jknullphenotype.RHDzygosity testing by bloodTyper was 100% concordant with a combination of hybrid Rhesus box PCR and PCR–restriction fragment length polymorphism for all samples.CONCLUSION: The automated bloodTyper software was modified for WES biases to allow for accurate RBC and PLT antigen typing. Such analysis could become a routing part of future WES efforts.

1 July 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PLPatrick C. Lee
Patrick C. Lee
SKSusan Klaeger
Susan Klaeger
PLPhuong M. Le
Phuong M. Le
KKKeegan Korthauer
Keegan Korthauer
JCJingwei Cheng
Jingwei Cheng
DKDerin B. Keskin
Derin B. Keskin
Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I–low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain- and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC.